Clearmind Gains IRB Approval At TASMC For Alcohol Use Disorder Drug Trial

Clearmind Medicine Inc. (CMND) has secured Institutional Review Board (IRB) approval from Tel Aviv Sourasky Medical Center (TASMC) for its Phase 1/2a trial of CMND-100, an MEAI-based oral drug targeting Alcohol Use Disorder (AUD). This approval enables patient enrollment at TASMC, expanding the multinational, multicenter trial which also includes Yale and Johns Hopkins, following the recent initial participant dosing. The trial aims to evaluate CMND-100's safety, tolerability, and preliminary efficacy in reducing alcohol cravings, with CMND shares trading up 10.7420% to $1 on the NasdaqCM in response to the news.

Analysis

Clearmind Medicine Inc. (CMND) has achieved a positive operational milestone by securing Institutional Review Board (IRB) approval from Tel Aviv Sourasky Medical Center (TASMC) for its Phase 1/2a trial of CMND-100. This development expands the multinational trial for its MEAI-based oral drug targeting Alcohol Use Disorder (AUD), adding another reputable institution alongside Yale School of Medicine and Johns Hopkins University. The approval follows prior critical regulatory hurdles, including FDA IND clearance and the recent dosing of the first trial participant, indicating steady progress in its clinical program. The market has responded favorably to this execution, with CMND's stock rising 10.7420% to $1.00. The trial's objective is to establish safety, tolerability, and preliminary efficacy data for a novel psychedelic-derived treatment in a market with a significant unmet need, as AUD is cited as being responsible for 4.7% of global deaths.

Key Decisions for Investors

• The consistent achievement of regulatory milestones, including this IRB approval and prior FDA clearance, signals strong operational execution and may be viewed as a positive catalyst for the stock.
• Investors should closely monitor future clinical data readouts regarding CMND-100's safety, tolerability, and preliminary efficacy, as these will be the primary drivers of long-term value and the next major inflection point.
• While the news is positive, the company remains in the early clinical stage (Phase 1/2a), meaning significant development and regulatory risks persist, a key consideration given the stock's recent price appreciation.